Behrman Capital has sold WIL Research Holdings Co. to an undisclosed financial sponsor for $500 million. WIL is an interdisciplinary non-clinical contract research organizations, providing product safety and toxicological assessment research and services primarily to the pharmaceutical, biotechnology, chemical and agricultural industries. Behrman says that the deal generated 3.6x cash-on-cash return, and a 63% IRR. www.wilresearch.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.